Dr. Reddy's Laboratories Stock Forecast
NYSE: RDYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 12.20 0.00%
RDY analyst consensus
Consensus (5 analysts)
none
Avg. price target
$13.22+8.36%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Dr. Reddy's Laboratories (2026-10-07), 2 rate the stock a buy or strong buy, 2 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $13.22, with a high estimate of $15.23 and a low estimate of $11.24. The average target implies upside of 8.4% from the current price of $12.20.
The spread between the highest and lowest targets is 35.5%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RDY.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 40% |
| Hold | 2 | 40% |
| Sell | 1 | 20% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $11.24 | -7.87% |
| Average target | $13.22 | +8.36% |
| High target | $15.23 | +24.84% |